Although genomics has provided a mass of molecular information to investigate the aetiology of cancer, most cancers still lack adequate long-term, sustainable therapy. This is especially so for glioblastoma, which is characterised by a relatively small and dispersed patient population, and highly specialised and often novel treatment regimens (requiring the engagement of regulatory authorities during development).